Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma (scientific article published on 21 November 2019)

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Q29547903

Hepatocellular carcinoma

Q29616359

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Q29617585

Systemic therapy for advanced hepatocellular carcinoma: an update

Q33593213

Epithelial-mesenchymal transitions and hepatocarcinogenesis

Q33755466

New knowledge of the mechanisms of sorafenib resistance in liver cancer

Q33759933

SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma

Q34347235

A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells

Q35274443

The synthesis and chemistry of certain anthelmintic benzimidazoles

Q35907917

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Q36610990

Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell

Q36748786

Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma

Q37049104

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus

Q37252935

Molecular mechanisms of hepatocellular carcinoma

Q37323726

A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma

Q37706507

Cellular and molecular mechanisms of hepatocellular carcinoma: an update

Q38046107

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

Q38282800

Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review

Q38283833

Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations

Q38533025

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

Q38546409

Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.

Q38702281

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Q38785510

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Q38812372

Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin

Q38816132

A benzimidazole derivative (RCB15) in vitro induces the alternative energetic metabolism and glycolysis in Taenia crassiceps cysticerci

Q38964537

Cancer Statistics, 2017.

Q39038674

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth

Q39251374

Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity

Q39301043

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.

Q39425929

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Q39612275

Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus

Q39678869

Synthesis of novel benzofuran and related benzimidazole derivatives for evaluation of in vitro anti-HIV-1, anticancer and antimicrobial activities.

Q40205581

Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells

Q41127791

Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.

Q41846145

Synthesis and biological activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives against some protozoa and Trichinella spiralis

Q43079663

Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles.

Q45961608

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

Q46183882

Synthesis and in vitro antimicrobial activity of some novel substituted benzimidazole derivatives having potent activity against MRSA.

Q46417776

Suppression of Staphylococcus aureus biofilm formation and virulence by a benzimidazole derivative, UM-C162.

Q49437451

New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies

Q50062264

AASLD guidelines for the treatment of hepatocellular carcinoma

Q56172239

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances

Q58093758

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Q60142201

Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond

Q64122405

Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole

Q86714698

P4510

describes a project that uses

ImageJ

Q1659584

P433

issue

P304

page(s)

17259

P577

publication date